Glenmark Unveils Affordable Ropivacaine Generic for US Market
Glenmark Pharmaceuticals will launch a generic version of Ropivacaine Hydrochloride injection for local anesthesia in the US. Starting November 2025, the product will be available in various strengths. This addition enhances Glenmark's injectable portfolio and demonstrates a commitment to affordable healthcare solutions.
- Country:
- India
Glenmark Pharmaceuticals announced its plans to introduce a generic version of the Ropivacaine Hydrochloride injection in the United States market. This local anesthesia product will be distributed beginning November 2025.
The pharmaceutical company's subsidiary, Glenmark Pharmaceuticals Inc, will offer Ropivacaine Hydrochloride Injection in single-dose vials with strengths of 40 mg/20 ml, 150 mg/30 ml, and 200 mg/20 ml. The distribution strategy aims to broaden access to affordable medical solutions.
The injections are bioequivalent and therapeutically equivalent to Fresenius Kabi USA, LLC's Naropin injection. Glenmark's President & Business Head for North America, Marc Kikuchi, emphasized this launch as a significant expansion of their injectable portfolio, highlighting their commitment to providing quality and cost-effective medical alternatives.
Google News